These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

573 related articles for article (PubMed ID: 17177199)

  • 1. Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study.
    McIntyre A; Gendron A; McIntyre A
    Depress Anxiety; 2007; 24(7):487-94. PubMed ID: 17177199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in patients with generalized anxiety disorder and a history of inadequate treatment response: a randomized, double-blind study.
    Khan A; Atkinson S; Mezhebovsky I; She F; Leathers T; Pathak S
    Ann Clin Psychiatry; 2013 Nov; 25(4):E7-22. PubMed ID: 24199224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in patients with generalized anxiety disorder and a history of inadequate treatment response: a randomized, double-blind study.
    Khan A; Atkinson S; Mezhebovsky I; She F; Leathers T; Pathak S
    Ann Clin Psychiatry; 2014 Feb; 26(1):3-18. PubMed ID: 24660224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Venlafaxine extended-release: a review of its use in the management of major depression.
    Wellington K; Perry CM
    CNS Drugs; 2001; 15(8):643-69. PubMed ID: 11524036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.
    Lenox-Smith AJ; Jiang Q
    Int Clin Psychopharmacol; 2008 May; 23(3):113-9. PubMed ID: 18408525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].
    Olié JP; Gourion D; Montagne A; Rostin M; Poirier MF
    Encephale; 2009 Dec; 35(6):595-604. PubMed ID: 20004291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder.
    Silverstone PH; Salinas E
    J Clin Psychiatry; 2001 Jul; 62(7):523-9. PubMed ID: 11488362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quetiapine fumarate augmentation for patients with a primary anxiety disorder or a mood disorder: a pilot study.
    Chen YC; Chen CK; Wang LJ
    BMC Psychiatry; 2012 Sep; 12():162. PubMed ID: 23020711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms.
    Davidson JR; Meoni P; Haudiquet V; Cantillon M; Hackett D
    Depress Anxiety; 2002; 16(1):4-13. PubMed ID: 12203668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder.
    Katila H; Mezhebovsky I; Mulroy A; Berggren L; Eriksson H; Earley W; Datto C
    Am J Geriatr Psychiatry; 2013 Aug; 21(8):769-84. PubMed ID: 23567397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study.
    El-Khalili N; Joyce M; Atkinson S; Buynak RJ; Datto C; Lindgren P; Eriksson H
    Int J Neuropsychopharmacol; 2010 Aug; 13(7):917-32. PubMed ID: 20175941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study.
    Hirschfeld RM; Weisler RH; Raines SR; Macfadden W;
    J Clin Psychiatry; 2006 Mar; 67(3):355-62. PubMed ID: 16649820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pooled analysis of adjunct extended-release quetiapine fumarate in patients with major depressive disorder according to ongoing SSRI or SNRI treatment.
    Bauer M; Demyttenaere K; El-Khalili N; Thase ME; Papakostas GI; Szamosi J; Earley WR; Eriksson H
    Int Clin Psychopharmacol; 2014 Jan; 29(1):16-25. PubMed ID: 24108148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
    Hewett K; Gee MD; Krishen A; Wunderlich HP; Le Clus A; Evoniuk G; Modell JG
    J Psychopharmacol; 2010 Aug; 24(8):1209-16. PubMed ID: 19939870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double-blind, randomized study of extended release quetiapine fumarate (quetiapine XR) monotherapy in older patients with generalized anxiety disorder.
    Mezhebovsky I; Mägi K; She F; Datto C; Eriksson H
    Int J Geriatr Psychiatry; 2013 Jun; 28(6):615-25. PubMed ID: 23070803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo.
    Entsuah AR; Huang H; Thase ME
    J Clin Psychiatry; 2001 Nov; 62(11):869-77. PubMed ID: 11775046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Venlafaxine extended release in the short-term treatment of depressed and anxious primary care patients with multisomatoform disorder.
    Kroenke K; Messina N; Benattia I; Graepel J; Musgnung J
    J Clin Psychiatry; 2006 Jan; 67(1):72-80. PubMed ID: 16426091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression.
    Schatzberg A; Roose S
    Am J Geriatr Psychiatry; 2006 Apr; 14(4):361-70. PubMed ID: 16582045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.
    Gelenberg AJ; Lydiard RB; Rudolph RL; Aguiar L; Haskins JT; Salinas E
    JAMA; 2000 Jun; 283(23):3082-8. PubMed ID: 10865302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended release quetiapine fumarate as adjunct to antidepressant therapy in patients with major depressive disorder: pooled analyses of data in patients with anxious depression versus low levels of anxiety at baseline.
    Bandelow B; Bauer M; Vieta E; El-Khalili N; Gustafsson U; Earley WR; Eriksson H
    World J Biol Psychiatry; 2014 Feb; 15(2):155-66. PubMed ID: 24506289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.